Literature DB >> 25792360

Homozygous MED25 mutation implicated in eye-intellectual disability syndrome.

Lina Basel-Vanagaite1, Pola Smirin-Yosef, Jenna Lee Essakow, Shay Tzur, Irina Lagovsky, Idit Maya, Metsada Pasmanik-Chor, Adva Yeheskel, Osnat Konen, Naama Orenstein, Monika Weisz Hubshman, Valerie Drasinover, Nurit Magal, Gaby Peretz Amit, Yael Zalzstein, Avraham Zeharia, Mordechai Shohat, Rachel Straussberg, Didier Monté, Mali Salmon-Divon, Doron M Behar.   

Abstract

Genetic syndromes involving both brain and eye abnormalities are numerous and include syndromes such as Warburg micro syndrome, Kaufman oculocerebrofacial syndrome, Cerebro-oculo-facio-skeletal syndrome, Kahrizi syndrome and others. Using exome sequencing, we have been able to identify homozygous mutation p.(Tyr39Cys) in MED25 as the cause of a syndrome characterized by eye, brain, cardiac and palatal abnormalities as well as growth retardation, microcephaly and severe intellectual disability in seven patients from four unrelated families, all originating from the same village. The protein encoded by MED25 belongs to Mediator complex or MED complex, which is an evolutionary conserved multi-subunit RNA polymerase II transcriptional regulator complex. The MED25 point mutation is located in the von Willebrand factor type A (MED25 VWA) domain which is responsible for MED25 recruitment into the Mediator complex; co-immunoprecipitation experiment demonstrated that this mutation dramatically impairs MED25 interaction with the Mediator complex in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25792360     DOI: 10.1007/s00439-015-1541-x

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  33 in total

1.  Structure and allosteric regulation of the alpha X beta 2 integrin I domain.

Authors:  Thomas Vorup-Jensen; Christian Ostermeier; Motomu Shimaoka; Ulrich Hommel; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-28       Impact factor: 11.205

2.  WHAT IF: a molecular modeling and drug design program.

Authors:  G Vriend
Journal:  J Mol Graph       Date:  1990-03

Review 3.  Mediator and the mechanism of transcriptional activation.

Authors:  Roger D Kornberg
Journal:  Trends Biochem Sci       Date:  2005-05       Impact factor: 13.807

4.  QMEAN: A comprehensive scoring function for model quality assessment.

Authors:  Pascal Benkert; Silvio C E Tosatto; Dietmar Schomburg
Journal:  Proteins       Date:  2008-04

5.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

Review 6.  The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation.

Authors:  Sohail Malik; Robert G Roeder
Journal:  Nat Rev Genet       Date:  2010-10-13       Impact factor: 53.242

7.  The CC2D1A, a member of a new gene family with C2 domains, is involved in autosomal recessive non-syndromic mental retardation.

Authors:  L Basel-Vanagaite; R Attia; M Yahav; R J Ferland; L Anteki; C A Walsh; T Olender; R Straussberg; N Magal; E Taub; V Drasinover; A Alkelai; D Bercovich; G Rechavi; A J Simon; M Shohat
Journal:  J Med Genet       Date:  2005-07-20       Impact factor: 6.318

8.  MAFFT multiple sequence alignment software version 7: improvements in performance and usability.

Authors:  Kazutaka Katoh; Daron M Standley
Journal:  Mol Biol Evol       Date:  2013-01-16       Impact factor: 16.240

9.  Mediator-dependent recruitment of TFIIH modules in preinitiation complex.

Authors:  Cyril Esnault; Yad Ghavi-Helm; Sylvain Brun; Julie Soutourina; Nynke Van Berkum; Claire Boschiero; Frank Holstege; Michel Werner
Journal:  Mol Cell       Date:  2008-08-08       Impact factor: 17.970

10.  ConSurf 2005: the projection of evolutionary conservation scores of residues on protein structures.

Authors:  Meytal Landau; Itay Mayrose; Yossi Rosenberg; Fabian Glaser; Eric Martz; Tal Pupko; Nir Ben-Tal
Journal:  Nucleic Acids Res       Date:  2005-07-01       Impact factor: 16.971

View more
  6 in total

Review 1.  Disorders of Transcriptional Regulation: An Emerging Category of Multiple Malformation Syndromes.

Authors:  Kosuke Izumi
Journal:  Mol Syndromol       Date:  2016-09-02

2.  Improving the phenotype description of Basel-Vanagaite-Smirin-Yosef syndrome, MED25-related: polymicrogyria as a distinctive neuroradiological finding.

Authors:  Ilenia Maini; Edoardo Errichiello; Stefano Giuseppe Caraffi; Orsetta Zuffardi; Livia Garavelli; Simonetta Rosato; Veronica Bizzarri; Marzia Pollazzon; Gabriele Trimarchi; Gianluca Contrò; Benedetta Cavirani; Chiara Gelmini; Manuela Napoli; Claudio Moratti; Rosario Pascarella; Susanna Rizzi; Carlo Fusco
Journal:  Neurogenetics       Date:  2020-08-20       Impact factor: 2.660

3.  Report of a Second Lebanese Family with Basel-Vanagaite-Smirin-Yosef Syndrome: Possible Founder Mutation.

Authors:  Pratibha Nair; Sandra Sabbagh; Sami Bizzari; Florian Brunner; Samantha Stora; Mahmoud T Al-Ali; Martin Gencik; Stephany El-Hayek; André Mégarbané
Journal:  Mol Syndromol       Date:  2019-06-28

Review 4.  Transcription Pause and Escape in Neurodevelopmental Disorders.

Authors:  Kristel N Eigenhuis; Hedda B Somsen; Debbie L C van den Berg
Journal:  Front Neurosci       Date:  2022-05-09       Impact factor: 5.152

5.  Structure of mammalian Mediator complex reveals Tail module architecture and interaction with a conserved core.

Authors:  Haiyan Zhao; Natalie Young; Jens Kalchschmidt; Jenna Lieberman; Laila El Khattabi; Rafael Casellas; Francisco J Asturias
Journal:  Nat Commun       Date:  2021-03-01       Impact factor: 14.919

6.  Mediator complex proximal Tail subunit MED30 is critical for Mediator core stability and cardiomyocyte transcriptional network.

Authors:  Changming Tan; Siting Zhu; Zee Chen; Canzhao Liu; Yang E Li; Mason Zhu; Zhiyuan Zhang; Zhiwei Zhang; Lunfeng Zhang; Yusu Gu; Zhengyu Liang; Thomas G Boyer; Kunfu Ouyang; Sylvia M Evans; Xi Fang
Journal:  PLoS Genet       Date:  2021-09-10       Impact factor: 5.917

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.